Lingohr Asset Management GmbH Acquires New Shares in BioNTech SE (NASDAQ:BNTX)

Lingohr Asset Management GmbH bought a new position in shares of BioNTech SE (NASDAQ:BNTX) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 3,170 shares of the company’s stock, valued at approximately $357,000.

A number of other large investors have also recently added to or reduced their stakes in BNTX. FMR LLC increased its holdings in BioNTech by 797.8% during the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC bought a new position in BioNTech during the 3rd quarter worth about $59,485,000. Braidwell LP bought a new position in BioNTech during the 3rd quarter worth about $29,425,000. abrdn plc increased its holdings in BioNTech by 70.7% during the 4th quarter. abrdn plc now owns 385,668 shares of the company’s stock worth $43,947,000 after purchasing an additional 159,676 shares in the last quarter. Finally, Redmile Group LLC bought a new position in BioNTech during the 3rd quarter worth about $18,345,000. Institutional investors own 15.52% of the company’s stock.

Wall Street Analyst Weigh In

BNTX has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on BioNTech in a report on Wednesday, December 11th. They set an “overweight” rating and a $170.00 target price for the company. Truist Financial assumed coverage on shares of BioNTech in a research note on Friday, January 10th. They set a “buy” rating and a $172.00 price objective for the company. BMO Capital Markets increased their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 11th. Canaccord Genuity Group restated a “buy” rating and set a $171.44 price objective on shares of BioNTech in a research note on Tuesday, March 11th. Finally, Citigroup assumed coverage on shares of BioNTech in a research note on Thursday, March 13th. They set a “buy” rating and a $145.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $143.73.

BioNTech Stock Up 0.3 %

BioNTech stock opened at $99.27 on Thursday. The stock has a market cap of $23.80 billion, a P/E ratio of -47.27 and a beta of 0.30. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49. The company’s 50-day moving average price is $114.09 and its two-hundred day moving average price is $113.44.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.19 billion for the quarter, compared to analysts’ expectations of $1.24 billion. During the same period in the prior year, the firm earned $1.90 EPS. The business’s revenue was down 19.5% on a year-over-year basis. As a group, analysts expect that BioNTech SE will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.